LIMN
Liminatus Pharma, Inc. Class A Common StockNASDAQ
Healthcare • Biotechnology
Updated 1 day ago
Coverage limited
$3.41-1.16%
Close Oct 13, 2026
- Market cap
- $1.62M
- 1 month
- -3.1%
- 3 months
- -28.1%
- 1 year
- -95.1%
- Dividend
- No dividends on record
- Short interest
- 4.8% of float44.6K shares · settled Sep 30, 2026 · -24.2% since Sep 15, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- —
- Net income
- -$12.52M
- Free cash flow
- -$3.99M
- Book value
- $300.61K
- Total debt
- $1.44M
- P/E
- —
- Price / sales
- —
- Price / book
- —
- FCF yield
- —
- Net margin
- —
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if LIMN is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
0 top institutions tracked
as of 2026-Q2 (filed 2026-09-22)
Insider context
Sentiment: unknown
No recent insider trades detected.
Red flags: 2
Largest 13-F holders · Q2 2026
14 filers reported a long position in LIMN for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Cygnus Capital Advisors, LLC | $36K | 329.3K | -5.9% |
| XTX Topco Ltd | $24.5K | 221.8K | New |
| GEODE CAPITAL MANAGEMENT, LLC | $15.3K | 138.4K | +17.5% |
| CITADEL ADVISORS LLC | $6.2K | 56.1K | -91.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | $5.5K | 50.4K | Unchanged |
| GOLDMAN SACHS GROUP INC | $4.4K | 40.2K | New |
| StoneX Group Inc. | $3.9K | 26.1K | New |
| VANGUARD FIDUCIARY TRUST CO | $2.5K | 23K | Unchanged |
| STATE STREET CORP | $2.1K | 19K | Unchanged |
| UBS Group AG | $1.8K | 16.7K | -69.3% |
Get the Full Analysis for LIMN
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.